Piper Sandler on Altimmune (ALT): 'An opportune Time to Buy Ahead of IMPACT Data'
Tweet Send to a Friend
Piper Sandler analyst Yasmeen Rahimi reiterated an Overweight rating and $25.00 price target on Altimmune (NASDAQ: ALT).The analyst commented: "ALT ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
